Compare RELY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | RCUS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2021 | 2018 |
| Metric | RELY | RCUS |
|---|---|---|
| Price | $13.01 | $21.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $24.90 | ★ $28.89 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,544,865,000.00 | $240,000,000.00 |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.57 | N/A |
| P/E Ratio | $135.81 | ★ N/A |
| Revenue Growth | ★ 31.27 | N/A |
| 52 Week Low | $12.08 | $6.50 |
| 52 Week High | $27.32 | $26.40 |
| Indicator | RELY | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 42.95 |
| Support Level | $12.10 | $19.91 |
| Resistance Level | $13.07 | $22.29 |
| Average True Range (ATR) | 0.50 | 1.10 |
| MACD | -0.11 | -0.19 |
| Stochastic Oscillator | 32.35 | 18.35 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.